Willem E. Fibbe MD, PhD.

Willem E. Fibbe MD, Ph.D. is emeritus professor of Hematology and Stem Cell Biology at the Departments of Internal Medicine at the Leiden University Medical Centre (LUMC). He studied medicine at the Free University in Amsterdam.

He completed his PhD in 1988 (cum laude) and became Head of the Bone Marrow Transplantation Program in 1991. In 2005 he was appointed as head of the Department of Immunohematology and Blood Transfusion. In 2007 he was appointed Chairman Division IV of the LUMC. He has been a member of the Commission for Advanced Therapies (CAT) of the European Medicines Agency (EMA) and is an active member of the Central Committee for Research on Human Subjects in the Netherlands (CCMO). He has been a member of several advisory committees of the National Health Council and is the chairman of the Hematology Working Group of WHO-ICD11 and a member of WHO’s Medical and Scientific Advisory Committee for ICD-11. He is a member of the Committee for Scientific Affairs of the American Society of Hematology (ASH) and chairs the Governance Committee of the European Hematology Association (EHA). He has been an Associate Editor of Blood and President of the EHA. In 2015 he co-founded the Leiden Regenerative Medicine Platform (LRMP) and since 2017 he is Chief Scientific Officer of Starfish Innovations. In 2018 he was awarded Knight in the Order of the Lion of the Netherlands.

Prof. Fibbe chaired the Regenerative Medicine Research Profile at LUMC and University of Leiden.

His primary research interest is in the field of hematopoietic stem cell biology and regenerative medicine, focusing on cellular therapies, including mesenchymal stromal cells, tissue repair and the hematopoietic stem cell niche.